NASDAQ:LXRX Lexicon Pharmaceuticals (LXRX) Stock Forecast, Price & News $2.74 +0.04 (+1.48%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.66▼$2.8150-Day Range$2.31▼$3.4952-Week Range$1.31▼$3.79Volume3.72 million shsAverage Volume3.08 million shsMarket Capitalization$520.34 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Lexicon Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside155.0% Upside$7.00 Price TargetShort InterestBearish3.40% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.59) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector717th out of 983 stocksPharmaceutical Preparations Industry358th out of 486 stocks 3.3 Analyst's Opinion Consensus RatingLexicon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Lexicon Pharmaceuticals has a forecasted upside of 155.0% from its current price of $2.75.Amount of Analyst CoverageLexicon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.40% of the outstanding shares of Lexicon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverLexicon Pharmaceuticals has a short interest ratio ("days to cover") of 8.5.Change versus previous monthShort interest in Lexicon Pharmaceuticals has recently increased by 30.83%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLexicon Pharmaceuticals does not currently pay a dividend.Dividend GrowthLexicon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LXRX. Previous Next 3.7 News and Social Media Coverage News SentimentLexicon Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Lexicon Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest94 people have searched for LXRX on MarketBeat in the last 30 days. This is an increase of 755% compared to the previous 30 days.MarketBeat Follows11 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 1,000% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.80% of the stock of Lexicon Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.59) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexicon Pharmaceuticals is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexicon Pharmaceuticals is -4.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexicon Pharmaceuticals has a P/B Ratio of 5.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lexicon Pharmaceuticals (NASDAQ:LXRX) StockLexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.Read More Receive LXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LXRX Stock News HeadlinesJune 2, 2023 | finance.yahoo.comWhy Lexicon Pharmaceuticals Stock Crashed This WeekJune 2, 2023 | americanbankingnews.comLexicon Pharmaceuticals (NASDAQ:LXRX) Price Target Increased to $8.00 by Analysts at CitigroupJune 4, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.June 2, 2023 | msn.comUnusual Call Option Trade in Lexicon Pharmaceuticals (LXRX) Worth $10.27KJune 1, 2023 | msn.comLexicon Pharma Declines after Stock OfferingJune 1, 2023 | seekingalpha.comLexicon Pharmaceuticals Secures Key FDA Approval, But Heavy Lifting RemainsJune 1, 2023 | marketwatch.comLexicon Pharmaceuticals Shares Drop 21% After Public Offering PricesJune 1, 2023 | finance.yahoo.comLexicon Announces Pricing of $125 Million Public Offering and Concurrent Private PlacementJune 4, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.June 1, 2023 | americanbankingnews.comLexicon Pharmaceuticals (NASDAQ:LXRX) Sees Large Volume IncreaseMay 31, 2023 | msn.comCitigroup Maintains Lexicon Pharmaceuticals (LXRX) Buy RecommendationMay 30, 2023 | msn.comHP, Lexicon Pharmaceuticals And 3 Stocks To Watch Heading Into TuesdayMay 27, 2023 | finanznachrichten.deLexicon Pharmaceuticals, Inc.: Lexicon Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart FailureMay 26, 2023 | markets.businessinsider.comFDA Approves Lexicon Pharma's Inpefa For Treatment Of Heart FailureMay 26, 2023 | reuters.comU.S. FDA approves Lexicon Pharma's heart failure drugMay 26, 2023 | finance.yahoo.comLexicon Announces FDA Approval of INPEFA™ (sotagliflozin) for Treatment of Heart FailureMay 26, 2023 | finance.yahoo.comUPDATE 2-U.S. FDA approves Lexicon Pharma's drug for heart failureMay 22, 2023 | americanbankingnews.comLexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at StockNews.comMay 19, 2023 | seekingalpha.comLexicon Pharmaceuticals: May 27 PDUFA Date For Heart Failure Drug Looks CrucialMay 11, 2023 | finance.yahoo.comWall Street's Counting on an FDA Nod for This Growth Stock to Nearly Double, but Should You?May 10, 2023 | finance.yahoo.comNew Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart FailureMay 4, 2023 | finance.yahoo.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2023 Earnings Call TranscriptMay 3, 2023 | finance.yahoo.comQ1 2023 Lexicon Pharmaceuticals Inc Earnings CallMay 2, 2023 | seekingalpha.comLexicon Pharmaceuticals, Inc. (LXRX) Q1 2023 Earnings Call TranscriptMay 2, 2023 | finance.yahoo.comLexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateApril 28, 2023 | finance.yahoo.comLexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023April 22, 2023 | finance.yahoo.comShould You Buy This Growth Stock Right Now Before It Potentially Doubles?See More Headlines LXRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LXRX Company Calendar Last Earnings11/03/2021Today6/04/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LXRX Previous SymbolNASDAQ:LEXG CUSIP52887210 CIK1062822 Webwww.lexpharma.com Phone(281) 863-3000Fax281-863-8010Employees87Year Founded1995Price Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+155.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,940,000.00 Net Margins-87,620.63% Pretax Margin-87,620.63% Return on Equity-105.14% Return on Assets-66.81% Debt Debt-to-Equity Ratio0.55 Current Ratio5.38 Quick Ratio5.38 Sales & Book Value Annual Sales$140,000.00 Price / Sales3,716.73 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book5.97Miscellaneous Outstanding Shares189,560,000Free Float176,672,000Market Cap$520.34 million OptionableOptionable Beta1.28 Social Links Key ExecutivesLonnel CoatsChief Executive Officer & DirectorJeffrey L. WadePresident & Chief Financial OfficerCraig B. GranowitzChief Medical Officer & Senior Vice PresidentBrian T. CrumSecretary, Senior Vice President & General CounselKiernan A. SethChief Commercial Officer & Vice PresidentKey CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTEmergent BioSolutionsNYSE:EBSVanda PharmaceuticalsNASDAQ:VNDARigel PharmaceuticalsNASDAQ:RIGLSpectrum PharmaceuticalsNASDAQ:SPPIView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 29,193 shares on 5/18/2023Ownership: 1.744%Geode Capital Management LLCBought 117,468 shares on 5/16/2023Ownership: 0.910%State Street CorpBought 47,623 shares on 5/16/2023Ownership: 0.825%Susquehanna International Group LLPBought 29,900 shares on 5/16/2023Ownership: 0.000%Jane Street Group LLCBought 4,592 shares on 5/16/2023Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions LXRX Stock - Frequently Asked Questions Should I buy or sell Lexicon Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LXRX shares. View LXRX analyst ratings or view top-rated stocks. What is Lexicon Pharmaceuticals' stock price forecast for 2023? 3 equities research analysts have issued twelve-month target prices for Lexicon Pharmaceuticals' stock. Their LXRX share price forecasts range from $3.00 to $10.00. On average, they expect the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 155.0% from the stock's current price. View analysts price targets for LXRX or view top-rated stocks among Wall Street analysts. How have LXRX shares performed in 2023? Lexicon Pharmaceuticals' stock was trading at $1.91 at the beginning of 2023. Since then, LXRX stock has increased by 43.7% and is now trading at $2.7450. View the best growth stocks for 2023 here. Are investors shorting Lexicon Pharmaceuticals? Lexicon Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 6,450,000 shares, an increase of 30.8% from the April 30th total of 4,930,000 shares. Based on an average trading volume of 756,900 shares, the days-to-cover ratio is presently 8.5 days. View Lexicon Pharmaceuticals' Short Interest. When is Lexicon Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our LXRX earnings forecast. How were Lexicon Pharmaceuticals' earnings last quarter? Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. The biopharmaceutical company earned $0.02 million during the quarter. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 105.14% and a negative net margin of 87,620.63%. During the same quarter in the prior year, the firm posted $0.71 earnings per share. What ETFs hold Lexicon Pharmaceuticals' stock? ETFs with the largest weight of Lexicon Pharmaceuticals (NASDAQ:LXRX) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO? 9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Lexicon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). What is Lexicon Pharmaceuticals' stock symbol? Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX." Who are Lexicon Pharmaceuticals' major shareholders? Lexicon Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.98%), FMR LLC (2.76%), JPMorgan Chase & Co. (1.74%), Pinnacle Associates Ltd. (1.03%), Geode Capital Management LLC (0.91%) and State Street Corp (0.83%). Insiders that own company stock include International SCA Artal and James F Tessmer. View institutional ownership trends. How do I buy shares of Lexicon Pharmaceuticals? Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lexicon Pharmaceuticals' stock price today? One share of LXRX stock can currently be purchased for approximately $2.75. How much money does Lexicon Pharmaceuticals make? Lexicon Pharmaceuticals (NASDAQ:LXRX) has a market capitalization of $520.34 million and generates $140,000.00 in revenue each year. The biopharmaceutical company earns $-101,940,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. How can I contact Lexicon Pharmaceuticals? Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The official website for the company is www.lexpharma.com. The biopharmaceutical company can be reached via phone at (281) 863-3000, via email at cschultz@lexpharma.com, or via fax at 281-863-8010. This page (NASDAQ:LXRX) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.